Skip to main content

Table 4 Factors associated with adherence in exposed HCWs/HCSs on HIV post-exposure prophylaxis

From: Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana

Characteristic Adherence Status1 Crude hazard ratio [95 % CI] p-value Adjusted hazard ratio [95 % CI] p-value
Adhered Defaulted
Drug regimen       
3TC/AZT −28 days 42 33 1.00   1.00  
3TC/AZT-3 days 101 0 1.79 [1.25–2.56] 0.002 1.75 [1.16–2.66] 0.008
3TC/AZT/LPV-RTV −28 days 32 20 1.10 [0.69–1.74] 0.688 1.02 [0.56–1.88] 0.938
Gender       
Female 102 29 1.00    
Male 73 24 0.97 [0.72–1.31] 0.824 - -
Age range (years)       
18–30 129 32 1.00    
31–40 34 16 0.85 [0.58–1.24] 0.395   
41–50 6 4 0.75 [0.33–1.70] 0.489   
>51 6 1 1.07 [0.47–2.43] 0.872 - -
Risk assessment       
Low 103 11 1.00   1.00  
Medium 36 20 0.71 [0.49–1.04] 0.079 0.91 [0.60–1.39] 0.672
High 36 22 0.69 [0.47–1.00] 0.052 1.05 [0.56–2.00] 0.871
Type of exposure       
Percutaneous 165 46 1.00    
Mucocutaneous 10 7 0.75 [0.40–1.42] 0.382 - -
Profession       
Nurses 65 17 1.00    
HCS 19 5 1.00 [0.60–1.67] 0.996   
Laboratory Staff 9 7 0.71 [0.35–1.43] 0.335   
Medical Doctors 59 18 0.97 [0.68–1.38] 0.850   
Ward Attendants 23 6 1.00 [0.62–1.61] 0.998 - -
  1. 1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16) were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval